

Health Care Market Oversight

Excellere and SuperCare

The [Health Care Market Oversight](#) (HCMO) program reviews health care business deals to make sure they support Oregon's goals of health equity, lower costs, increased access, and better care. On January 28, 2026, the Oregon Health Authority (OHA) accepted a complete notice of material change describing plans for Excellere Capital Fund IV, LP ("Excellere") to acquire Super Care, Inc. ("SuperCare").

Who's involved?

Excellere is a privately-held investment firm based in Denver, Colorado. Excellere's portfolio companies span multiple industries including water treatment, logistics, auto insurance, molecular testing, pharmacy, infusion therapy, and engineering. AIS Healthcare is a specialty pharmacy and is the only one of Excellere's portfolio companies that operates in Oregon. In 2025, AIS Healthcare served approximately 238 patients in Oregon.

SuperCare is a privately-held corporation headquartered in Downey, California. SuperCare has two primary lines of business: complex respiratory durable medical equipment (DME) and pharmacy services. SuperCare provides ventilation therapy, airway clearance, sleep therapy, oxygen, respiratory medication, and home medical equipment and supplies across California, Nevada, New Mexico, Arizona, and Oregon. In 2024, SuperCare served approximately 7,500 patients in Oregon through three subsidiaries: Rick's Medical Supply, Inc., Sound Sleep Solutions, LLC., and Hucek Enterprises.

About the deal

Excellere is proposing to acquire 77% indirect ownership interest in SuperCare. According to the entities, the acquisition of SuperCare will provide additional financial resources and expertise to SuperCare, allowing for the continuation of respiratory care services and broader access in Oregon. Additionally, the entities state that they do not expect any immediate changes to SuperCare's locations, services provided, or areas serviced.

What's next?

OHA is reviewing this deal to understand how it could affect access to care for communities in Oregon. During the review, OHA will use health care data, news and media reports, information from the entities, and public input to decide whether the deal should be approved. After completing a review, OHA will issue a decision about whether the deal may proceed as planned.

We want to hear from you!

Public input helps us understand how this deal could help or harm people in your community. To share your thoughts about this deal, please email hcmo.info@oha.oregon.gov, leave a voicemail at 503-945-6161, or [fill out the public](#)

You can get this document in other languages, large print, braille, or a format you prefer free of charge. Contact us by email at hcmo.info@oha.oregon.gov or by phone at 503-945-6161. We accept all relay calls.

Health Care Market Oversight

[comment form](#). In your comment, mention "Excellere", what you think, and whether you support or oppose the deal.